Lumos Pharma Inc.

2 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

0 Completed trials

5 Countries active

1 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase III: 1 Phase II: 1

Top indications

Congenital growth hormone deficiency 1

Top IMPs

IBUTAMOREN MESILATE 2

All trials

2 total

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Tr… Not authorised

2025-523820-26-00 Phase III 5 countries IBUTAMOREN MESILATE
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency Recruiting

2023-504020-25-00 Phase II 1 country IBUTAMOREN MESILATE

Showing 1–2 of 2 trials

← All sponsors A–Z